Latest Fusion protein Stories
PLANTATION, Fla., Jan.
Selexis SA announced today the first therapeutic biologic generated with the Selexis SUREtechnology Platform™ has been approved for market. Geneva, Switzerland
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus™ Libraries Can Dramatically Improve Biologic Protein Expression in Mammalian Cell Lines Geneva, Switzerland
SAN DIEGO, Jan.
Reportbuyer.com just published a new market research report:
MarketResearchReports.Biz announces addition of new report “Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend” to its database.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.